Investor Alert

New York Markets Close in:

Market Pulse Archives

Jan. 30, 2020, 4:28 p.m. EST

Vertex Pharma stock rises on earnings, outlook beat

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Vertex Pharmaceuticals Inc. (VRTX)

or Cancel Already have a watchlist? Log In

By Wallace Witkowski


Vertex Pharmaceuticals Inc. /zigman2/quotes/202259802/composite VRTX -2.42% shares rose in the extended session Thursday after the biotech drug maker's results and forecast topped Wall Street estimates. Vertex shares rose 2.9% after hours, following a 0.9% decline in the regular session to close at $230.31. The company reported fourth-quarter net income of $583.2 million, or $2.23 a share, compared with $1.55 billion, or $5.97 a share, in the year-ago period. Adjusted earnings were $1.70 a share versus $1.30 a share in the year-ago period. Revenue rose to $1.41 billion from $870.1 million in the year-ago quarter. Analysts surveyed by FactSet had forecast earnings of $1.21 a share on revenue of $1.01 billion. Vertex expects "total product" revenue of $5.1 billion to $5.3 billion in 2020, while analysts had forecast on revenue of $4.88 billion.

US : U.S.: Nasdaq
$ 287.96
-7.15 -2.42%
Volume: 490,033
July 16, 2020 1:32p
P/E Ratio
Dividend Yield
Market Cap
$76.52 billion
Rev. per Employee

Get news alerts on Vertex Pharmaceuticals Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.